Medicilon is a professional preclinical integrated R&D contract research organization (CRO), providing a full range of one-stop R&D services, in compliance with international and Chinese filing standards, to pharmaceutical companies and institutions around the world. Our services cover the entire process of preclinical drug development, including hit discovery, lead optimization and candidate selection. Our drug discovery services include chemical synthesis, compound activity screening and optimization, structural biology research and target validation. Preclinical services we provide include process and formulation development, quality standards and stability testing, and biomarker development. We also provide a full range of pharmacodynamic, pharmacokinetic and toxicological safety assessment to support IND applications.

We focus on meeting the innovation and development needs of the global drug development industry.

Medicilon is a pharmaceutical R&D and contract research organization (CRO) based in Shanghai and Boston. We have created a comprehensive technical service platform that integrates compound synthesis, activity screening, structural biology, pharmacodynamic evaluation, pharmacokinetic evaluation, toxicology evaluation and supporting new drug filings. We operate in compliance with international standards and are recognized by international drug administrations. In February 2008, Medicilon established Medicilon Preclinical Research (Shanghai) LLC, a subsidiary with a focus on preclinical pharmacokinetics and safety evaluation research. MPI’s animal experiment facilities have been accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), and have obtained NMPA GLP and FDA GLP certification. Our integrated services help clients achieve their R&D goals efficienciently for minimal time and cost.